Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | ECE1 | P42892 | 6/20 | 0.48 |
| ▸ | MME | P08473 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323941 | 0.88 | ACE (0.56) | CTSKECE1MMECAPN1CTSS | |
| SCHEMBL13323970 | 0.88 | MME (0.55) | CTSKECE1MMEFOLH1SIRT2 | |
| SCHEMBL13323971 | 0.88 | MME (0.48) | CTSKECE1MMEFOLH1CAPN1 | |
| SCHEMBL13323948 | 0.87 | CTSB (0.57) | CTSKECE1MMEPSMB5CTSS | |
| SCHEMBL13324000 | 0.87 | CTSK (0.53) | CTSKECE1MMECYP1A2FOLH1 | |
| SCHEMBL13323943 | 0.87 | MME (0.56) | CTSKECE1MMECTSL | |
| SCHEMBL29372806 | 0.87 | MME (0.61) | CTSKECE1MMEFOLH1CAPN1 | |
| SCHEMBL13323973 | 0.85 | SIRT2 (0.59) | ECE1MMEFOLH1SIRT2SIRT1 | |
| SCHEMBL13323962 | 0.85 | MME (0.54) | CTSKECE1MMECTSSCTSL | |
| SCHEMBL10871797 | 0.84 | MME (0.63) | CTSKECE1MMEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | CTSK 1427/4885ECE1 3200/4885MME 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.